絞り込み

16426

広告

奄美ノネコ捕獲計画案、1週間期限譲渡先探す - 読売新聞

読売新聞奄美ノネコ捕獲計画案、1週間期限譲渡先探す読売新聞世界自然遺産登録を目指す奄美大島で野生化したネコ(ノネコ)が固有種を襲っている問題で、環境省と鹿児島県...

  1. 福島第1、屋根カバー設置を完了 (デイリ...
  2. Tesla、パブリッククラウド環境に不正...
  3. どうなる、地球温暖化時代の「冬季五輪」 ...
  4. [企業] Ionis 腎疾患治療アンチセ...

ニュース一覧

Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.

著者 Yang X , Li Y , Sun Y , Zhang M , Guo C , Mirza IA , Li YQ
Dig Dis Sci.2017 Dec 27 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (47view , 0users)

Full Text Sources

Although proton pump inhibitors (PPIs) have been used widely, acid-related diseases are still associated with a huge burden on the health care system. Recently, the efficacy and safety of a new acid suppressant named vonoprazan in the treatment of acid-related diseases have been evaluated by a series of studies. As a novel potassium-competitive acid blocker, vonoprazan may provide reversible acid suppression by preventing K+ from binding to gastric H+/K+-ATPase. It has been clinically used for the short-term treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori (H. pylori) infection in Japan. The healing rate of GERD and gastric ulcers by vonoprazan is more than 95 and 90%, respectively; also, it is effective in curing PPI-resistant GERD. It increases H. pylori eradication rate to more than 88% as part of both first-line and second-line therapy. It is also effective in the eradication of clarithromycin-resistant H. pylori strains. All of these short-term studies show vonoprazan is safe and well-tolerated. As a safe and effective acid inhibitor, vonoprazan might be a novel alternative in the treatment of acid-related diseases.
PMID: 29282636 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード